The Food and Drug Administration has approved abaloparatide (Tymlos) for postmenopausal women with osteoporosis at high risk for fracture.
The investigational neurokinin 3 receptor antagonist fezolinetant successfully and safely reduced hot flushes in postmenopausal women.
A better understanding of the physical and anatomic changes during menopause has led to improved treatments for vulvovaginal atrophy (also known...
A large Danish cohort study clarifies the risk factors for depression after a diagnosis of breast cancer, which include advanced age,...
From the Journals
Denosumab, taken long term, is not linked with any adverse events, an analysis of the participants in the FREEDOM trial showed.
Open power morcellation now is contraindicated in perimenopausal and postmenopausal women. What is Johns Hopkins’ protocol in this new climate? An...
ORLANDO – The novel approach reduced hot flashes without the need for estrogen in a phase II trial.
News for Your Practice
New data from the SWAN study reveal that African American women have the longest median duration of vasomotor symptoms, at 10.1 years, and...
ORLANDO – Phase III trial results represent another step toward FDA approval of a formulation of bioidentical hormone therapy to treat hot flashes...
Prescribing systemic hormone therapy is common, but controversial. Dr. Kaunitz elaborates on specific dosing and tapering patients, as well as...
Could the lower postmenopausal coronary artery calcium scores seen in HT users be linked to lower all-cause mortality?